-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
BioNexus Gene Lab Corp annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from 2019 to 2024.
- BioNexus Gene Lab Corp Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $16K, a 886% increase year-over-year.
- BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2024 was $12.3K, a 29.1% decline from 2023.
- BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2023 was $17.4K.
- BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2022 was -$3.9K, a 85.4% increase from 2021.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)